1.	Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00509, E1505, U10CA021115, ECOG-E1505, SWOG-E1505, CALGB-E1505, CAN-NCIC-E1505, NCCTG-E1505, NCT00324805
2.	Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: STU 052011-093, NCT01459497
3.	A Phase I/II Trial of Stereotactic Body Radiation Therapy Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 06-0691 / 201012832, NCT00591838
4.	Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 100138, 10-C-0138, NCT01143545
5.	Dose-Escalation and Safety Trial of YN968D1 Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BK-LSK-AM101, NCT01497704
6.	Intensity-Modulated Scanning Beam Proton Therapy (IMPT) With Simultaneous Integrated Boost (SIB) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2011-1058, 5P01CA021239-32, NCT01629498
7.	A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AT13387-05, 2012-001575-37, NCT01712217
8.	Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11-094, 902168, NCT01720836
9.	A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LUN005-12, NCT01770418
10.	SRS Study in Patients With Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2005-0574, NCT00489008
11.	Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: I 124407, RPCI-I-124407, NCT00843726
12.	Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: INST 0810, NCI-2011-02943, NCT00832780
13.	Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SCRI LUN 186, NCT00906282
14.	Image-Guided Adaptive Conformal Photon Versus Proton Therapy Phase: Phase II Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: 2008-0133, NCT00915005
15.	Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: OSI-906-205, 2010-020916-12, NCT01186861
16.	STEREOtactic Radiation and Chemotherapy in Lung Cancer (STEREO) Phase: Phase II Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: BCC-LUN-10-STEREO, NCT01300299
17.	Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11-106, NCT01443078
18.	Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CCCWFU 99311, U10CA081851, WFU 09-10-14, NCT01535040
19.	Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2011-0691, P01 CA021239, NCT01511081
20.	Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy Phase: Phase II Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2012-0347, NCT01636934
21.	Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: BrUOG 259, NCT01656460
22.	Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 07-RAD-01, NCT01657617
23.	Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CCL5001-01, NCT00062907
24.	Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer Phase: Phase I Type: Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 05-219, NCT00264602
25.	Phase 1b Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC) Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 1341-2004, NCT00401778